To include your compound in the COVID-19 Resource Center, submit it here.

Dermira data could bolster bid as Dupixent alternative

Dermira added $80 million to its market cap Friday on detailed Phase IIb data that lend additional support to the idea that its atopic dermatitis therapy could compete with Dupixent on dosing.

Dermira Inc. (NASDAQ:DERM) reported top-line data in

Read the full 386 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE